Sanofi (NYSE:SNY) said yesterday that it is suing competitor Novo Nordisk (NYSE:NVO) for “misleading” marketing materials that claim Sanofi’s insulin drugs Lantus and Toujeo will be “blocked” by U.S. pharmacy benefit manager CVS Caremark in January and that patients should switch to Nordisk’s Tresiba.
CVS is replacing both Sanofi’s and Nordisk’s drugs with Eli Lilly’s Basaglar on its standard formulary, but Sanofi said that many health plans don’t follow CVS’s standard list and even those that do will probably continue to cover the company’s drugs.
Get the full story at our sister site, Drug Delivery Business News.
The post Sanofi sues Nordisk over Tresiba marketing claims in U.S. appeared first on MassDevice.
from MassDevice http://ift.tt/2htbv31
Interesting Article. Hoping that you will continue posting an article having a useful information. Coolsculpting Santa Clara
ResponElimina